COVID-19 Puts Spotlight On Clinical Trial Networks: 'We Really Need Them Right Now'
Executive Summary
Duke-Margolis' Mark McClellan touts the advantages networks have over individual operations, citing the dexamethasone RECOVERY trial, and notes need for real-world evidence infrastructure.
You may also be interested in...
EU Platform Trials Project Piques WHO’s Interest
The World Health Organization is developing a new best practice guideline on improving the quality and efficiency of clinical trials and is keen to learn what role platform trials can play on this front and their acceptability by the clinical trial community.
UK Is First To Sign Up Pfizer For COVID-19 Vaccine, AstraZeneca For Antibodies
The UK's vaccine strategy spread its bets over three candidates so far, as the country also looks to prove its world-class status in life sciences research and manufacturing.
Shared Control: Novel Trial Design Works In COVID, But Will Sponsors Buy In?
COVID-19 has helped demonstrate the viability of platform trials with a shared control arm. That model is easier to extol than it is for sponsors to embrace, especially outside of crisis mode.